{"filings":[{"id":746560,"accession_number":"0001683168-26-004387","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2026-05-29T20:05:43+00:00","items":["5.07"],"status":"ready","headline":"Majority shareholder approves >20% stock issuance at discount; warrant adjustments allowed","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO Dr. Steve N. Slilaty, holding ~86% voting power, approved issuance of >20% of outstanding shares at discount to Nasdaq min price.","Consent allows adjustment of Series C Warrants' exercise price or shares in a Share Combination Event.","Consent allows voluntary adjustment of Series C Warrant exercise prices from time to time.","Consent effective 20 days after mailing definitive info statement; part of May 19, 2026 public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":526722,"accession_number":"0001683168-26-004116","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2026-05-19T20:05:46+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.","Each unit includes one share (or pre-funded warrant) plus two Series C warrants exercisable at $0.50 for five years.","Potential additional $12.0M if Series C warrants fully exercised; no assurance given.","Net proceeds for general corporate purposes and working capital.","Aegis Capital Corp acted as placement agent with 7% fee plus 2% expense allowance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92648,"accession_number":"0001683168-26-002781","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sunshine Biopharma reports FY 2025 revenue $36.3M (+4.1% YoY), net loss $5.98M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $36.31M vs $34.87M in 2024; gross profit $12.26M up from $10.67M.","Net loss widened to $5.98M from $5.13M, including $1.75M non-cash impairment charge.","Launched 9 new generic drugs in 2025, portfolio now 71 products; 12 more planned in 2026.","Raised $2.46M gross via registered direct offering to expand sales operations.","Cost-reduction initiatives expected to cut G&A by $2M-$3M in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":8088765.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103625,"accession_number":"0001683168-26-001609","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sunshine Biopharma hires Aegis Capital as warrant solicitation agent for 3 months, 10% fee on proceeds","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Engaged Aegis Capital on March 6, 2026 to induce exercise of outstanding warrants on best-efforts basis.","Term of engagement agreement is three months; Aegis receives 10% of gross proceeds from warrant exercises.","Company agreed to reimburse Aegis up to $100,000 for legal fees and expenses.","Engagement includes exclusivity provision: Company cannot solicit other financing during term except existing debt holders.","Warrants trade under ticker SBFMW on Nasdaq; proceeds would provide non-dilutive capital to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103624,"accession_number":"0001683168-26-001216","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Majority shareholder approves reverse stock split up to 1-for-10 for Sunshine Biopharma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Steve N. Slilaty, holding ~96% voting power, approved by written consent a reverse split of common stock up to 1-for-10.","Board has discretion on whether to effect the reverse split and the exact ratio (whole number up to 1-for-10).","Shareholder consent will be effective 20 days after mailing definitive information statement to stockholders.","Dr. Slilaty is CEO and controls approximately 96% of total voting power."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103623,"accession_number":"0001683168-26-000789","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sunshine Biopharma COO Dr. Abderrazzak Merzouki resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Abderrazzak Merzouki resigned as COO of Sunshine Biopharma on February 5, 2026, effective immediately.","No replacement or interim COO has been announced in the filing.","The resignation is reported under Item 5.02 with no stated reason for departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119886,"accession_number":"0001683168-25-009103","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sunshine Biopharma shareholders elect all five directors and approve equity plan increase at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Dr. Slilaty, Sebaaly, Kiderchah, Natan, Keller received over 130M votes for.","Ratification of M&K CPAS as independent auditor for 2025 approved with 132M for, 178K against.","Amendment to 2023 Equity Incentive Plan to increase authorized shares to 683,000 approved with 130M for, 294K against.","Broker non-votes: 1.77M on director elections and equity plan; 0 on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136451,"accession_number":"0001683168-25-007338","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Sunshine Biopharma dismisses Bush & Associates, appoints M&K CPAS as auditor effective Sept 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Bush & Associates CPA LLC as independent auditor on Sept 24, 2025; no prior disagreements or reportable events.","Retained M&K CPAS, PLLC as new independent registered public accounting firm effective same date.","Audit reports for fiscal years 2023 and 2024 were unqualified; no adverse opinions or modifications.","Company requested Bush & Associates to provide letter agreeing with disclosures; letter not yet received, will be filed by amendment.","Change approved by board and audit committee; no consultations with M&K prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153614,"accession_number":"0001683168-25-003838","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.","Net loss improved to $1.18M from $1.28M in prior-year quarter.","Appointed Michel Roy as new Chief Commercial Officer.","Launched 6 new generic drugs: two antibiotics, two GI drugs, two schizophrenia drugs.","Completed preclinical studies confirming K1.1 mRNA-LNP activity against hepatocellular carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":8901341.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153613,"accession_number":"0001683168-25-002245","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sunshine Biopharma closes $2.46M registered direct offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $2.46M from sale of 1,188,404 shares of common stock (or pre-funded warrants) at $2.07 per share.","Net proceeds of approximately $1.8M after deducting offering expenses; funds to be used for general corporate purposes and working capital.","Pre-funded warrants exercisable immediately at $0.001 per share; expire when exercised in full.","Offering closed on April 3, 2025; Aegis Capital acted as exclusive placement agent.","Pricing was at the market under Nasdaq rules; shelf registration statement effective January 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153612,"accession_number":"0001683168-25-002193","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.","Net loss $5.1M vs $4.5M in FY2023; G&A expenses $16.5M, up from $13.1M.","Completed ~$10M underwritten public offering for expansion of sales operations.","Launched 13 new generic drugs; received Health Canada approval for oncology drug NIOPEG.","Published PLpro inhibitor study in J. Med. Chem.; completed mouse model proof-of-concept for K1.1 mRNA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":8901341.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172318,"accession_number":"0001683168-25-000357","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sunshine Biopharma appoints Michel Roy as Chief Commercial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michel Roy appointed CCO effective Jan 13, 2025; initial base salary of $400,000 CAD annually.","Severance of $500,000 CAD payable if terminated without cause, plus minimum statutory notice.","Roy previously led Canadian ops of Shilpa Medicare (2020-2024) and was VP at Intas Pharmaceuticals (2014-2020).","Responsibilities include overseeing commercial strategy, sales, marketing, and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189316,"accession_number":"0001683168-24-008607","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sunshine Biopharma annual meeting: all director nominees elected with >130M votes, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Steve Slilaty, Dr. Merzouki, Dr. Kiderchah, Mr. Natan, Dr. Keller each elected with over 130M votes FOR.","Ratification of Bush & Associates CPA LLC as auditor: 130,089,305 FOR, 15,456 AGAINST, 11,725 abstain.","Meeting held December 10, 2024; all director nominees were elected with zero broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189315,"accession_number":"0001683168-24-007758","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.","Q3 net loss $(1.20M) compared to $(0.65M) in Q3 2023, a YoY increase of 84%.","YTD net loss $(2.98M) vs $(3.26M) in prior year period, an improvement of 9%.","Shareholders' equity grew 18% to $25.04M from $21.21M at Dec 31, 2023.","Growth driven by new product launches and expanded marketing via Canadian subsidiary Nora Pharma."],"consensus_eps_estimate":-0.1326,"consensus_eps_actual":-13.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":25279291.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189314,"accession_number":"0001683168-24-007323","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sunshine Biopharma enters new employment agreements with CEO, CFO, COO; CEO severance of $14M USD","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Slilaty: $543,753 CAD base salary, 5% or CPI annual increase, $14M USD severance for termination without cause or for good reason.","CFO Camille Sebaaly: $411,000 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.","COO Dr. Merzouki: $328,800 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.","All three executives to devote 90% of time to subsidiary Nora Pharma Inc.; agreements effective retroactive to January 1, 2024.","CEO's $14M USD severance is substantially larger relative to base salary than CFO and COO severance of $2M CAD each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205810,"accession_number":"0001683168-24-006281","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sunshine Biopharma regains Nasdaq bid-price compliance; faces 1-year monitoring with strict delisting risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with Bid Price Rule (Listing Rule 5550(a)(2)).","Subject to Mandatory Panel Monitor for one year from September 9, 2024.","If non-compliant during monitoring, no cure period allowed; Nasdaq will issue Delist Determination Letter.","Company may request a new hearing if delist determination is issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205809,"accession_number":"0001683168-24-005903","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sunshine Biopharma Q2 revenue $9.3M (+67% YoY); net loss narrows 45% to $(494K)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 gross revenue $9,303,067, up 67% from $5,560,865 in Q2 2023.","Net loss for Q2 2024 was $(494,300) vs $(902,108) in Q2 2023, a 45% improvement.","YTD revenue $16,844,113, up 61% from $10,454,918; YTD net loss $(1,778,101) improved 32%.","Sequential Q2 sales grew 23% over Q1 2024 sales of $7,541,046.","Shareholders' equity $23,489,865, up 11% from Dec 31, 2023."],"consensus_eps_estimate":-0.1122,"consensus_eps_actual":-43.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":16844113.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205808,"accession_number":"0001683168-24-005496","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sunshine Biopharma announces 1-for-20 reverse stock split, effective Aug 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-20 reverse stock split effective August 8, 2024; each share converted to one-twentieth of a share.","Certificate of amendment filed with Colorado Secretary of State on August 7, 2024.","Reverse split applies to all outstanding shares of common stock; no change in authorized shares or par value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205807,"accession_number":"0001683168-24-004601","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Majority shareholder approves up to 60-for-1 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Steve Slilaty, holding 84.8% voting power, approved reverse split by written consent.","Reverse split ratio up to 60-for-1 of common stock.","Effective 20 days after mailing definitive information statement to shareholders.","Dr. Slilaty is CEO and controls majority voting power."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205806,"accession_number":"0001683168-24-004572","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sunshine Biopharma gets Nasdaq bid-price extension to Aug 26, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Hearings Panel exception until August 26, 2024 to regain minimum bid price compliance.","Must achieve closing bid price of at least $1.00 for 10 consecutive business days by deadline.","Company was previously notified of deficiency under Listing Rule 5550(a)(2).","Failure to meet conditions may result in delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222795,"accession_number":"0001683168-24-004120","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"All Series A Warrants exercised by holders as of June 11, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Series A Warrants issued on Feb 15, 2024 fully exercised as of June 11, 2024.","No details on number of warrants, exercise price, or total proceeds provided.","Exercise may result in dilution but share count impact not disclosed.","Company did not specify use of proceeds from the warrant exercises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222794,"accession_number":"0001683168-24-004053","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Sunshine Biopharma of delisting due to warrant dilution","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq staff determined to delist SBFM under Rule 5101 citing public interest concerns over Series A warrant cashless exercise provision.","Provision allowed warrant holders to receive 2x shares without adjusting for 1-for-100 reverse split on April 17, 2024, causing massive shareholder dilution.","Company must present views to Nasdaq Hearings Panel by June 14, 2024; no immediate effect on listing pending panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222793,"accession_number":"0001683168-24-003777","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.","Net loss of $(1,283,801) improved from $(1,702,430) in the prior-year quarter.","Gross profit rose to $2,354,337 from $1,828,122, driven by new product launches.","In February 2024, completed public offering for gross proceeds of ~$10 million.","Growth attributed to expanded sales efforts by subsidiary Nora Pharma Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":7541046.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222792,"accession_number":"0001683168-24-003104","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Sunshine Biopharma appoints Bush & Associates as new auditor, eff. May 7, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bush & Associates CPA LLC engaged as independent registered public accounting firm as of May 7, 2024.","Decision approved by unanimous board consent; no prior consultations with new auditor reported.","No disagreements or reportable events in the past two fiscal years or subsequent interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222791,"accession_number":"0001683168-24-003004","cik":1402328,"company_name":"Sunshine Biopharma Inc.","ticker":"SBFM","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Sunshine Biopharma dismisses auditor BF Borgers after SEC permanent ban","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BF Borgers CPA, PC was dismissed as independent auditor after SEC settled charges and permanently banned the firm.","Borgers' audit reports for fiscal years 2022 and 2023 contained no adverse opinions or qualifications.","No disagreements or reportable events occurred with Borgers during the relevant periods.","Dismissal approved by audit committee; Borgers' letter agreeing with disclosures filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2124522.9637454986,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}